Vimarsana
Biggest News Aggregation in the World

Page 41 - Eceptor News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Eceptor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Eceptor Today - Breaking & Trending Today

Ketamine's long-lasting antidepressant effects unveiled in new study - Vimarsana News

Ketamine's long-lasting antidepressant effects unveiled in new study

Persistent blocking of NMDAR and burst-type firing by lateral habenula (LHb) neurons may offer a basis for the long-lasting antidepressant effects of ketamine.

Novel GLP-1 receptor agonists offer hope for long-lasting diabetes treatment - Vimarsana News

Novel GLP-1 receptor agonists offer hope for long-lasting diabetes treatment

In a study published in Scientific Reports, researchers engineer long-lasting GLP-1 receptor agonists by fusing GLP-1 with an HSA-binding protein. These chimeric molecules show promise for the treatment of type 2 diabetes due to their stability, functionality, and high affinity for the GLP-1 receptor and human serum albumin.

Groundbreaking study reveals most effective adjunctive drug for Parkinson's disease - Vimarsana News

Groundbreaking study reveals most effective adjunctive drug for Parkinson's disease

The efficacy, tolerability, and safety of various anti-Parkinson's drugs.

How ketamine treatment elicits long-lasting anti-depressive effects - Vimarsana News

How ketamine treatment elicits long-lasting anti-depressive effects

Researchers discuss the mechanisms responsible for the sustained antidepressant effects of ketamine by examining ketamine-NMDAR interactions.

New funding from Breast Cancer Now supports research on treatment-resistant ER-positive breast cancer - Vimarsana News

New funding from Breast Cancer Now supports research on treatment-resistant ER-positive breast cancer

Researchers are investigating how the most common type of breast cancer resists hormone therapy, thanks to new funding from Breast Cancer Now.